This presentation features summary analyses of several recent articles on OUD treatment from the Addiction Medicine research literature. Using an abbreviated "journal club" format, the presentation reviews each paper, examining context, methods and results, interpretation of scientific findings, and implications for clinical practice.
Learning Objectives
At the end of this educational activity, the learner will be able to:
- Identify emerging options for long-acting medication treatments for opioid use disorder (OUD)
- Contrast strengths and limitations of 2 extended-release buprenorphine formulations for the treatment of OUD
- Improve their ability to apply research results from the scientific literature into their everyday practices
Target Audience
Psychiatrists, Residents/Fellows, Non-psychiatrist physicians
Estimated Time to Complete
Estimated Duration: 1 hour
Program Start Date: April 26, 2021
Program End Date: April 26, 2024
How to Earn Credit
Participants who wish to earn AMA PRA Category 1 Credit ™ or a certificate of participation may do so by completing all sections of the course including the evaluation. After evaluating the program, course participants will be provided with an opportunity to claim hours of participation and print an official CME certificate (physicians) or certificate of participation (non-physicians) showing the completion date and hours earned.
Continuing Education Credit
The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The APA designates this enduring CME activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Faculty and Planner Disclosures
Presenters- Mark Fishman, M.D., Medical Director, Maryland Treatment Centers. Reports the following financial relationships with commercial interests: Stock - Maryland Treatment Centers; Consultant - Alkermes Drug Delivery LLC Am Soc Addiction Med Nat Assoc Drug Court Prog; Employee - Maryland Treatment Centers; Grant/Research - Alkermes NIDA.
Program Planners- Sejal Patel, American Psychiatric Association. Reports no financial relationships with commercial interests.
- Robert Schwartz, M.D., Medical Director/Senior Research Scientist, Friends Research Institute. Reports the following financial relationships with commercial interests: Consultant, Verily Life Sciences.
References
- Haight, BR et al. Efficacy and safety of a monthly buprenorphine depot injection for opioid use disorder: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2019 Feb;393(10173):778-790.
- Lofwall, MR et al. Weekly and monthly subcutaneous buprenorphine depot formulations vs daily sublingual buprenorphine with naloxone for treatment of opioid use disorder: a randomized clinical trial. JAMA Intern Med. 2018 Jun;178(6):764-773.
- Williams, R et al. Development of a cascade of care for responding to the opioid epidemic. Am J Drug Alcohol Abuse. 2019;45(1):1-10.
Accessibility for Participants with Disabilities
The American Psychiatric Association is committed to ensuring accessibility of its website to people with disabilities. If you have trouble accessing any of APA’s online resources, please contact us at 202-559-3900 for assistance.
Technical Requirements
This internet-based CME activity is best experienced using any of the following:
- The latest and 2nd latest public versions of Google Chrome, Mozilla Firefox, or Safari
- Internet Explorer 11+
This Web site requires that JavaScript and session cookies be enabled. Certain activities may require additional software to view multimedia, presentation, or printable versions of the content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Adobe Acrobat Reader, Microsoft PowerPoint, and Windows Media Player.
Optimal System Configuration:
- Browser: Google Chrome (latest and 2nd latest version), Safari (latest and 2nd latest version), Internet Explorer 11.0+, Firefox (latest and 2nd latest version), or Microsoft Edge (latest and 2nd latest version)
- Operating System: Windows versions 8.1+, Mac OS X 10.5 (Leopard) +, Android (latest and 2nd latest version), or iOS/iPad OS (latest and 2nd latest version)
- Internet Connection: 1 Mbps or higher
Minimum Requirements:
- Windows PC: Windows 8.1 or higher; 1 GB (for 32-bit)/2 GB (for 64-bit) or higher RAM; Microsoft DirectX 9 graphics device with WDDM driver; audio playback with speakers for programs with video content
- Macintosh: Mac OS X 10.5 or higher with latest updates installed; Intel, PowerPC G5, or PowerPC G4 (867MHz or faster) processor; 512 MB or higher RAM; audio playback with speakers for programs with video content
For assistance: Contact spatel@psych.org for questions about this activity | Contact learningcenter@psych.org for technical assistance